PhD Martina Gobec

PhD Martina Gobec
no.: 32034 source: ARIS

researcher – active in research organisation
  martina.gobecat signgmail.com
Edit
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   
3.01.00  Medical sciences  Microbiology and immunology   
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
726.91
A''
130.23
A'
388.61
A1/2
575.96
CI10
877
CImax
124
h10
17
A1
2.67
A3
0
Data for the last 5 years (citations for the last 10 years) on May 16, 2026; Data for score A3 calculation refer to period 2020-2024
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 60  1,042  830  13.83 
Scopus 59  1,136  903  15.31 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2008 
Doctoral degree  Ph. D.     SI University of Ljubljana, Faculty of Pharmacy 2012 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (120%, RD:26%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  12/1/2009  Assistant  Researcher  Associate professor 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. J3-70142  Charting new horizons: Unlocking the potential of NOD1, a versatile force in immunity   3/1/2026 - 2/28/2029  PhD Žiga Jakopin   846 
2. J1-70040  Synthesis and evaluation of natural products caerulomycins as pharmaceutical agents or building blocks in metallodrug design (SynCAER)   3/1/2026 - 2/28/2029  PhD Jakob Kljun   1,198 
3. N1-0417  Mono- and multivalent inhibitors of galectin-8 in tumour-associated (lymph)angiogenesis (MULTIGAL-8)   3/1/2025 - 9/30/2028  PhD Marko Anderluh   895 
4. J3-60066  Advanced post-neoadjuvant treatment of early triple negative breast cancer (TNBC) with autologous cell immunotherapy   1/1/2025 - 12/31/2027  PhD Simona Borštnar   2,986 
5. N1-0331  A double whammy for the NF-κB signalling pathway: development of TAK1 and IKKβ degraders against inflammation-driven diseases   1/1/2024 - 12/31/2027  PhD Izidor Sosič   1,174 
6. J1-50038  New Hsp90 Inhibitor-based Therapies for Ewing Sarcoma   1/1/2024 - 12/31/2026  PhD Tihomir Tomašić   1,282 
7. J1-50037  Development of CDK1-selective degraders for the treatment of T-cell malignancies   10/1/2023 - 9/30/2026  PhD Izidor Sosič   1,369 
8. J3-50116  Matters of the heart: elucidating the cardiotoxic mechanism of proteasome inhibitors   10/1/2023 - 9/30/2026  PhD Martina Gobec   2,534 
9. J3-4496  Next-generation adjuvants for mucosal vaccines   10/1/2022 - 9/30/2026  PhD Žiga Jakopin   1,541 
10. J3-3062  Autologous immunohybridomas and advanced treatment of stage II and III triple-negative breast cancer   10/1/2021 - 9/30/2025  PhD Matjaž Jeras   2,827 
11. L3-3176  The Role and Potential Application of Immunomodulatory Mesenchymal Stem Cells in COVID- 19 Disease   10/1/2021 - 9/30/2024  PhD Janja Zupan   3,772 
12. J3-2517  Development of innate immune receptor-targeting chimeras as custom-tailored vaccine adjuvants   9/1/2020 - 12/31/2023  PhD Žiga Jakopin   2,580 
13. J1-2483  Radiopharmaceuticals with antagonistic activity on CCK2R   9/1/2020 - 8/31/2023  PhD Marko Anderluh   1,242 
14. J1-2485  The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs   9/1/2020 - 8/31/2023  PhD Izidor Sosič   1,175 
15. J3-1745  Elucidating the role of immunoproteasome in platelet-driven immune response   7/1/2019 - 6/30/2023  PhD Martina Gobec   1,317 
16. J3-9256  Development of NOD2 agonists and dual NOD2/TLR7 agonistic conjugates as novel vaccine adjuvants   7/1/2018 - 6/30/2022  PhD Žiga Jakopin   3,200 
17. N1-0068  Identification of non-peptidic inhibitors of the immunoproteasome using fragment based drug discovery methods   11/1/2017 - 10/31/2020  PhD Stanislav Gobec   2,140 
18. J3-6792  TRANS TIO Translacijske farmakogenomske raziskave tiopurinske terapije (Slovene)   7/1/2014 - 6/30/2017  PhD Irena Mlinarič Raščan   1,794 
19. J3-5507  ANALIZA BIOLOŠKIH OZNAČEVALCEV PRESNOVE FOLATOV PRI UGOTAVLJANJU TVEGANJA ZA NASTANEK NAPAK NEVRALNE CEVI (Slovene)   8/1/2013 - 7/31/2016  PhD Ksenija Geršak   3,952 
20. J3-4285  Razvoj in ovrednotenje radiooznačenih bioloških molekul za ciljano radionuklidno terapijo nevroendokrinih tumorjev in spremljajočo diagnostiko (Slovene)   7/1/2011 - 6/30/2014  PhD Jurij Fettich   2,565 
21. J3-4220  Vloga genetskih polimorfizmov na izid zdravljenja in pojav zapletov pri otrocih z rakom (Slovene)   7/1/2011 - 6/30/2014  PhD Janez Jazbec   3,773 
22. J3-3615  Farmakogenetski pristop k raziskavam, diagnostiki in terapiji levkemij (Slovene)   5/1/2010 - 4/30/2013  PhD Irena Mlinarič Raščan   2,375 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0420  Advanced immunological drugs and cell-based approaches in pharmacy   1/1/2022 - 12/31/2027 PhD Žiga Jakopin   1,671 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,847 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,703 
Confirmation required
Views history
Favourite